NO994898L - Cytomodulering av lipofile peptider for å modulere immunsystemaktivitet og inhibere inflammasjon - Google Patents

Cytomodulering av lipofile peptider for å modulere immunsystemaktivitet og inhibere inflammasjon

Info

Publication number
NO994898L
NO994898L NO994898A NO994898A NO994898L NO 994898 L NO994898 L NO 994898L NO 994898 A NO994898 A NO 994898A NO 994898 A NO994898 A NO 994898A NO 994898 L NO994898 L NO 994898L
Authority
NO
Norway
Prior art keywords
cells
activity
lymphocytic
inhibiting
inhibit
Prior art date
Application number
NO994898A
Other languages
English (en)
Other versions
NO994898D0 (no
Inventor
Roland Buelow
Gerard Grassy
Bernard Calas
Original Assignee
Sangstat Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/028,083 external-priority patent/US6696545B1/en
Application filed by Sangstat Medical Corp filed Critical Sangstat Medical Corp
Publication of NO994898D0 publication Critical patent/NO994898D0/no
Publication of NO994898L publication Critical patent/NO994898L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO994898A 1997-04-11 1999-10-08 Cytomodulering av lipofile peptider for å modulere immunsystemaktivitet og inhibere inflammasjon NO994898L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83891697A 1997-04-11 1997-04-11
US09/028,083 US6696545B1 (en) 1997-04-11 1998-02-23 Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
PCT/US1998/007231 WO1998046633A1 (en) 1997-04-11 1998-04-10 Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Publications (2)

Publication Number Publication Date
NO994898D0 NO994898D0 (no) 1999-10-08
NO994898L true NO994898L (no) 1999-11-24

Family

ID=26703275

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994898A NO994898L (no) 1997-04-11 1999-10-08 Cytomodulering av lipofile peptider for å modulere immunsystemaktivitet og inhibere inflammasjon

Country Status (14)

Country Link
US (1) US7267822B2 (no)
EP (1) EP0973799B1 (no)
JP (1) JP4550171B2 (no)
CN (1) CN1216900C (no)
AT (1) ATE352556T1 (no)
AU (2) AU761717B2 (no)
BR (1) BR9808529B1 (no)
CA (1) CA2286478A1 (no)
IL (1) IL132310A0 (no)
NO (1) NO994898L (no)
NZ (1) NZ500287A (no)
PL (1) PL336302A1 (no)
TR (1) TR199902786T2 (no)
WO (1) WO1998046633A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773240B1 (fr) 1997-12-30 2002-11-29 Synt Em Procede pour prevoir, identifier et decrire des molecules susceptibles de presenter un comportement recherche, notamment dans le domaine de la pharmacie et molecules obtenues par ce procede
MXPA01010541A (es) * 1999-04-21 2003-08-19 Univ Georgia Res Found Cisteina proteasa e hinibidores para la prevencion y el tratamiento de la neurocisticercosis.
US7094413B2 (en) 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
KR20040094745A (ko) * 2002-02-26 2004-11-10 상스타트 메디칼 코포레이션 세포제거 요법에 의해 유도된 위장 독성을 치료하는 방법및 조성물
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
JP2006516546A (ja) * 2002-11-15 2006-07-06 サングスタット メディカル コーポレイション 間質性膀胱炎の治療用細胞調節性ペプチド
WO2005001075A1 (en) * 2003-05-15 2005-01-06 Sangstat Medical Corporation Rdp58 compositions and methods for modulating the activity of osteoclasts and osteoblasts
WO2005009457A1 (en) * 2003-05-15 2005-02-03 Sangstat Medical Corporation Rdp58 compositions and methods for inhibiting vascularization of cell populations
US7498309B2 (en) 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
CN104231054A (zh) * 2014-09-01 2014-12-24 王跃建 Il-10多肽抑制剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723128A (en) * 1987-01-30 1998-03-03 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides
EP0365525B1 (en) 1987-01-30 1995-08-09 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte inhibition by hla peptides
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US5385888A (en) * 1987-03-20 1995-01-31 The Regents Of The University Of California Class I MHC modulation or surface receptor activity
JP3015058B2 (ja) 1989-03-03 2000-02-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 表面レセプター活性のクラスｉｍｈｃ調節
NZ270605A (en) * 1991-08-26 1997-07-27 Cytel Corp Cytotoxic t lymphocyte inducing peptides (6-19 amino acids) and pharmaceutical compositions thereof
EP0661985B1 (en) 1991-11-08 1999-07-07 The Board Of Trustees Of The Leland Stanford Junior University Peptides capable of binding cd8 molecules on ctl precursors
US5440015A (en) 1992-07-21 1995-08-08 Glycomed Incorporated Selectin peptide medicaments for treating disease
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
CA2176208A1 (en) * 1993-11-10 1995-05-18 Carol Clayberger Surface membrane proteins and their effect on immune response
CA2181787A1 (en) * 1994-03-03 1995-09-08 Claire M. Doerschuk Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders
CA2210812C (en) * 1995-01-16 2009-09-01 Nicholas Manolios T-cell affecting peptides
US6162434A (en) * 1995-05-03 2000-12-19 Sangstat Medical Corporation Cytomodulating peptide for inhibiting lymphocyte activity
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
WO1997024140A1 (en) 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
US6436903B1 (en) 1996-05-22 2002-08-20 Stanford University (Board Of Trustees Of The Leland Standford Junior University) Immunomodulating compounds comprising d-isomers of amino acids
WO1997044351A1 (en) 1996-05-24 1997-11-27 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Also Published As

Publication number Publication date
NZ500287A (en) 2002-10-25
EP0973799B1 (en) 2007-01-24
ATE352556T1 (de) 2007-02-15
WO1998046633A1 (en) 1998-10-22
AU6897898A (en) 1998-11-11
AU2003244571A1 (en) 2003-10-02
PL336302A1 (en) 2000-06-19
JP2001526641A (ja) 2001-12-18
CN1259958A (zh) 2000-07-12
AU761717B2 (en) 2003-06-05
IL132310A0 (en) 2001-03-19
TR199902786T2 (xx) 2000-06-21
CA2286478A1 (en) 1998-10-22
AU2003244571B2 (en) 2007-07-05
EP0973799A1 (en) 2000-01-26
NO994898D0 (no) 1999-10-08
US7267822B2 (en) 2007-09-11
BR9808529B1 (pt) 2010-10-05
BR9808529A (pt) 2000-10-24
JP4550171B2 (ja) 2010-09-22
US20040248810A1 (en) 2004-12-09
CN1216900C (zh) 2005-08-31

Similar Documents

Publication Publication Date Title
TR199801168T2 (xx) �nterleukin-1 beta d�n��t�r�c� enzim inhibit�rleri.
ATE415173T1 (de) Pan dr-bindeproteinen zur erhöhung der immunantwort
EA199700135A1 (ru) Ингибиторы клеточной адгезии
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
Hong et al. Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells
PL348147A1 (en) Utilisation of dialkylfumarates
TR200000481T2 (tr) N-Alkonoilfenilalenin türevleri.
TR200001982T2 (tr) Farmasötik vurulu salınımlı oral dozaj şekli.
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
EA199800119A1 (ru) Ингибиторы адгезии клеток
NO992463D0 (no) N-(aryl/heteroarylacetyl)aminosyreestere, farmas°ytiske sammensetninger som omfatter det samme, og metoder for inhibering av <beta>-amyloidpeptidfrigivelse og/eller dens syntese ved bruk av slike forbindelser
TR200103428T2 (tr) IMPDH enzim inhibitörleri.
NO994898L (no) Cytomodulering av lipofile peptider for å modulere immunsystemaktivitet og inhibere inflammasjon
AU5314900A (en) Compositions and methods for inhibiting cell death
ATE286139T1 (de) Replikationskompetente anti-tumor vektoren
LV10108A (lv) Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni
NO971517D0 (no) Peptider og farmasöytiske sammensetninger omfattende dem
WO1990007321A3 (en) Lymphocyte receptor homing sequences and their uses
TR199802577T2 (xx) Ayr� b�lmelerde iki aktif terkip maddeli transdermik sistemler.
DE69807672T2 (de) Von milchsäure abgeleitete butyrat-prodrugs
Zaroukian SURFACE LY-5 GLYCOPROTEIN IN MURINE NATURAL KILLER (NK) CELL DEVELOPMENT, TARGET BINDING AND CYTOTOXICITY: FUNCTIONAL STUDIES AND PRELIMINARY BIOCHEMICAL CHARACTERIZATION.
NO910981L (no) Peptidforbindelser.
Jespersen THE EFFECT OF ALPHA-FETOPROTEIN (AFP) AND OTHER CORD SERUM FRACTIONS ON MITOGEN-INDUCED LYMPHOCYTE TRANSFORMATION AND THE ONE-WAY MIXED LYMPHOCYTE REACTION.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application